Zepbound is a weight-loss drug developed by Eli Lilly, approved by the U.S. Food and Drug Administration for chronic weight management in adults with obesity or overweight conditions. It contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which helps regulate appetite and blood sugar levels. Zepbound is part of a growing class of medications targeting metabolic health and obesity treatment.